Teratogen update: Methotrexate

Wiley - Tập 94 Số 4 - Trang 187-207 - 2012
Sara C. Hyoun1, Sarah Običan2, Anthony R. Scialli2,3
1George Washington University School of Medicine & Health Sciences, Washington, DC, USA
2Department of Obstetrics and Gynecology, George Washington University Medical Center and Reproductive Toxicology Center, Washington, D.C
3Tetra Tech Sciences, Arlington, Virginia

Tóm tắt

AbstractMethotrexate and aminopterin are folic acid antagonists that inhibit dihydrofolate reductase, resulting in a block in the synthesis of thymidine and inhibition of DNA synthesis. Methotrexate has been used for the treatment of malignancy, rheumatic disorders, and psoriasis and termination of intrauterine pregnancy. Recently, methotrexate has become a standard treatment for ectopic pregnancy. The misdiagnosis of an intrauterine pregnancy as an ectopic pregnancy can result in exposure of a continuing pregnancy to dose levels of methotrexate of 50 mg/m2 (maternal body surface area). Experimental animal studies have associated methotrexate therapy with embryo death in mice, rats, rabbits, and monkeys. Structural malformations have been most consistently produced in rabbits at a maternal dose level of 19.2 mg/kg. Abnormalities in rabbits include hydrocephalus, microphthalmia, cleft lip and palate, micrognathia, dysplastic sacral and caudal vertebrate, phocomelia, hemimelia, syndactyly, and ectrodactyly. Based on human case reports of methotrexate exposure during pregnancy, a methotrexate embryopathy has been described that includes growth deficiency, microcephaly, hypoplasia of skull bones, wide fontanels, coronal or lambdoidal craniosynostosis, upswept frontal scalp hair, broad nasal bridge, shallow supraorbital ridges, prominent eyes, low‐set ears, maxillary hypoplasia, epicanthal folds, short limbs, talipes, hypodactyly, and syndactyly. This syndrome may be associated with exposures between 6 and 8 weeks after conception and dose levels of 10 mg/week or greater. More recent case reports of methotrexate exposure for the misdiagnosis of ectopic pregnancy involve treatment before 6 weeks after conception and have raised the suggestion of a distinct syndrome due to such early exposures. Tetralogy of Fallot and perhaps other neural crest cell‐related abnormalities may be features of this early syndrome. A disproportionality analysis of methotrexate and aminopterin case reports and series provides support for pulmonary atresia, craniosynostosis, and limb deficiencies as reported more often than expected in methotrexate‐exposed children. Denominator‐based data will be welcome to better define elements of a methotrexate embryopathy and possibly to distinguish an early exposure syndrome from anomalies traditionally associated with methotrexate exposure. Birth Defects Research (Part A), 2012. © 2012 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

10.1097/00006250-200806000-00044

10.1002/ajmg.a.20503

10.1016/S1701-2163(16)30422-4

10.1002/ajh.2830360404

10.1056/NEJMcp0810384

10.1002/(SICI)1096-9926(199802)57:2<51::AID-TERA2>3.0.CO;2-9

Berry CL, 1971, Transient inhibition of DNA synthesis by methotrexate in the rat embryo and foetus, J Embryol Exp Morphol, 26, 469

Briggs GG, 2011, Drugs in pregnancy and lactation, 54

Brudie LA, 2011, Metastatic choriocarcinoma in a viable intrauterine pregnancy treated with EMA‐CO in the third trimester. a case report, J Reprod Med, 56, 359

10.1002/art.1780400527

Chakravarty EF, 2003, The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes, J Rheumatol, 30, 241

10.1016/S0029-7844(03)00120-0

10.1002/ajmg.a.33496

Correa A, 2007, Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report. Appendix A, Birth Defects Res (A), 79, 94

10.1002/tera.1420360111

10.1002/(SICI)1096-9926(199907)60:1<10::AID-TERA5>3.0.CO;2-H

10.1002/tera.1420230205

10.1002/tera.1420430304

10.1002/tera.1420450306

10.1002/tera.1420150211

10.1002/tera.1420490202

10.1002/tcm.1770120503

10.1056/NEJM194806032382301

10.1002/tera.1420470605

10.1111/j.1600-0412.2011.01093.x

10.1016/S0301-2115(99)00240-7

10.1038/sj.jp.7211563

10.1097/00001665-200309000-00027

Hahn I, 2001, Leucovorin rescue for malicious abortion attempt with methotrexate, J Toxicol Clin Toxicol 2001, 39, 507

Jones KL, 2006, Smith's recognizable patterns of human malformation, 658

10.1002/tera.1420150110

10.1002/tera.1420140104

10.1002/ajmg.a.34037

10.1002/pd.334

Lewden B, 2004, Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study, J Rheumatol., 31, 2360

10.1016/j.ijgo.2006.09.009

10.1016/j.jcjo.2011.05.001

10.1002/tera.1420320118

10.1016/S0029-7844(01)01607-6

10.1016/j.ajog.2011.07.002

Østensen M, 2000, Low dose weekly methotrexate in early pregnancy. A case series and review of the literature, J Rheumatol, 27, 1872

Østensen M, 2007, Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease, J Rheumatol, 34, 1266

10.1007/s00246-011-9913-z

10.1016/j.fertnstert.2011.06.014

10.1002/bdra.20199

10.1002/tera.1420090206

10.1007/s100249900069

10.1016/S0002-9378(16)38924-4

10.1016/0300-483X(75)90022-0

10.1016/j.ijgo.2007.05.039

10.1002/tera.10052

Wilson JG, 1971, Use of rhesus monkeys in teratological studies, Fed Proc, 30, 104

10.1002/tera.1420190111

10.1002/tera.1420170110

10.1097/01.AOG.0000154002.26761.41

Zand DJ, 2003, In utero methotrexate exposure resulting in long bone aplasia, Am J Hum Genet, 73, 591

Thông tin
Thông tin xuất bản

Wiley

Tập 94 Số 4

187-207

Thông tin tác giả